Category: Press Release - Page 36 - Psychedelic Alpha

Read more about the article Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects

Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects

Post published:December 12, 2022
Post category:Press Release

Read more about the article Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

Post published:December 12, 2022
Post category:Press Release

Read more about the article MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Post published:December 9, 2022
Post category:Press Release

Read more about the article COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

Post published:December 8, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT

Post published:December 8, 2022
Post category:Press Release

Read more about the article BetterLife Announces Closing of Private Placement

BetterLife Announces Closing of Private Placement

Post published:December 7, 2022
Post category:Press Release

Read more about the article Ehave Shareholder from CEO Ben Kaplan and Corporate Update

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

Post published:December 7, 2022
Post category:Press Release

Read more about the article Mindset Pharma to Participate in Upcoming Conferences in December 2022

Mindset Pharma to Participate in Upcoming Conferences in December 2022

Post published:December 6, 2022
Post category:Press Release

Read more about the article Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

Post published:December 6, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Post published:December 5, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.